製品番号: HY-B0637

ベザフィブラート

(別名: Bezafibrate; BM15075)

14 Cited Publications

カスタマーレビュー

Based on 14 publication(s) in Google Scholar

Bezafibrate is an agonist of PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.83%
CAS 番号: 41859-67-0
分子式: C₁₉H₂₀ClNO₄
分子量:361.82

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Bezafibrate 構造式

CAS 番号: 41859-67-0

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (14)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

hPPARδ

20 μM (EC₅₀)

hPPARα

50 μM (EC₅₀)

hPPARγ

60 μM (EC₅₀)

PPAR アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO-K1	EC₅₀	>137 μM Compound: Bezafibrate	Concentration of compound that affords half-maximum transactivation of human Peroxisome proliferator activated receptor gamma in CHO-K1 cells was determined in vitro Concentration of compound that affords half-maximum transactivation of human Peroxisome proliferator activated receptor gamma in CHO-K1 cells was determined in vitro	[PMID: 11738577]
CHO-K1	EC₅₀	>143 μM Compound: bezafibrate	Agonist activity on Gal4 chimeric human Peroxisome proliferator activated receptor delta expressed in CHO-K1 cells Agonist activity on Gal4 chimeric human Peroxisome proliferator activated receptor delta expressed in CHO-K1 cells	[PMID: 12904063]
CHO-K1	EC₅₀	>78 μM Compound: Bezafibrate	Transactivation of human Peroxisome proliferator activated receptor alpha expressed in CHO-K1 cells Transactivation of human Peroxisome proliferator activated receptor alpha expressed in CHO-K1 cells	[PMID: 11738577]
COS-7	EC₅₀	15.4 μM Compound: Bezafibrate	Agonist activity at Gal4-tagged human PPARgamma ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay Agonist activity at Gal4-tagged human PPARgamma ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay	10.1039/C6MD00042H
COS-7	EC₅₀	22.6 μM Compound: Bezafibrate	Agonist activity at Gal4-tagged human PPARdelta ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay Agonist activity at Gal4-tagged human PPARdelta ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay	10.1039/C6MD00042H
COS-7	EC₅₀	7.1 μM Compound: Bezafibrate	Agonist activity at Gal4-tagged human PPARalpha ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay Agonist activity at Gal4-tagged human PPARalpha ligand binding domain expressed in COS-7 cells measured after overnight incubation by dual-glo luciferase reporter gene assay	10.1039/C6MD00042H
CV-1	EC₅₀	100 μM Compound: 2, benzafibrate	Agonist activity at human PPARgamma expressed in monkey CV1 cells by transactivation assay Agonist activity at human PPARgamma expressed in monkey CV1 cells by transactivation assay	[PMID: 18280733]
CV-1	EC₅₀	110 μM Compound: 3	Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	20 μM Compound: 3	Compound was tested for agonist activity on human Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells Compound was tested for agonist activity on human Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	3 μM Compound: benzafibrate	Agonist activity at human PPARgamma expressed in CV1 cells by transactivation assay Agonist activity at human PPARgamma expressed in CV1 cells by transactivation assay	[PMID: 17964792]
CV-1	EC₅₀	30 μM Compound: 2, benzafibrate	Agonist activity at human PPARalpha expressed in monkey CV1 cells by transactivation assay Agonist activity at human PPARalpha expressed in monkey CV1 cells by transactivation assay	[PMID: 18280733]
CV-1	EC₅₀	30 μM Compound: 2, benzafibrate	Agonist activity at human PPARdelta expressed in monkey CV1 cells by transactivation assay Agonist activity at human PPARdelta expressed in monkey CV1 cells by transactivation assay	[PMID: 18280733]
CV-1	EC₅₀	30 μM Compound: benzafibrate	Agonist activity at human PPARalpha expressed in CV1 cells by transactivation assay Agonist activity at human PPARalpha expressed in CV1 cells by transactivation assay	[PMID: 17964792]
CV-1	EC₅₀	30 μM Compound: benzafibrate	Agonist activity at human PPARdelta expressed in CV1 cells by transactivation assay Agonist activity at human PPARdelta expressed in CV1 cells by transactivation assay	[PMID: 17964792]
CV-1	EC₅₀	50 μM Compound: 3	Compound was tested for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CV-1 cells Compound was tested for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	55 μM Compound: 3	Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	60 μM Compound: 3	Compound was tested for agonist activity on human Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells Compound was tested for agonist activity on human Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	90 μM Compound: 3	Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor transfected CV-1 cells Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor transfected CV-1 cells	[PMID: 10508427]
HEK293	EC₅₀	35.74 μM Compound: 1	Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay	[PMID: 23265844]
HEK293	EC₅₀	46.58 μM Compound: 1	Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay	[PMID: 23265844]
HEK293	EC₅₀	70.36 μM Compound: 1	Agonist activity at human PPARgamma expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay Agonist activity at human PPARgamma expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay	[PMID: 23265844]
HepG2	EC₅₀	1.04 μM Compound: BZF	Transactivation of PPAR transfected in human HepG2 cells after 20 hrs by luciferase reporter gene assay Transactivation of PPAR transfected in human HepG2 cells after 20 hrs by luciferase reporter gene assay	[PMID: 23031596]
HepG2	EC₅₀	1.05 μM Compound: Benzafibrate	Transactivation of PPAR expressed in HepG2 cells after 20 hrs by luminescence assay Transactivation of PPAR expressed in HepG2 cells after 20 hrs by luminescence assay	[PMID: 22381047]
HepG2	EC₅₀	18.9 μM Compound: 1	Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay	[PMID: 21215640]
HepG2	EC₅₀	42.5 μM Compound: 1	Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay	[PMID: 21215640]
HepG2	EC₅₀	57.2 μM Compound: 1	Agonist activity at human PPARgamma expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay Agonist activity at human PPARgamma expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay	[PMID: 21215640]
INS1(832/13)	EC₅₀	6 nM Compound: 36	Induction of glucose-stimulated insulin secretion in rat INS-1 832/13 cells incubated for 5 mins by ELISA assay Induction of glucose-stimulated insulin secretion in rat INS-1 832/13 cells incubated for 5 mins by ELISA assay	[PMID: 33771587]
Sf21	IC₅₀	231.7 μM Compound: Bezafibrate	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	391 μM Compound: Bezafibrate	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

体外実験

Bezafibrate is an agonist of PPAR, with EC₅₀s of 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, and 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, respectively^[1].
Bezafibrate (> 200 μM) shows significant cytotoxicity against human retinal microvascular endothelial cells (HRMECs) and human retinal pigment epithelial ARPE-19 cells. Bezafibrate (30-100 μM) suppresses tumor necrosis factor (TNF)α induced inflammatory factors and regulates TNFα induced nuclear factor (NF)-κB transactivation in HRMEC. Bezafibrate inhibits VEGF-induced HRMECs migration, and inhibits interleukin (IL)-1β-induced VEGF secretion of ARPE-19 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Bezafibrate (0.5%) markedly reduces plasma lipid and glucose levels, and increases islet area in the pancreas in TallyHo mice. Bezafibrate also improves energy expenditure and metabolic flexibility. Moreover, Bezafibrate ameliorates steatosis, modifies lipid composition and increases mitochondrial mass in the liver^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 41859-67-0
性状 Solid
分子量 361.82
分子式 C₁₉H₂₀ClNO₄
Color White to off-white
SMILES

CC(C)(OC1=CC=C(CCNC(C2=CC=C(Cl)C=C2)=O)C=C1)C(O)=O
別名

Bezafibrate; BM15075
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (14)

All Cell Imaging/StainingWBIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape. [Abstract]

2023 Dec 25;8(1):457. PMID: 38143263

Bezafibrate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [Abstract]

U87 cells with high EGFRvIII density were cocultured with EGFRvIII-targeted CAR-T cells, supplemented with indicated drugs. Cells were magnetically separated for CAR molecule detection. Representative immunoblotting images from three independent duplications showed that Atorvastatin (5μM, 3 days) and Cytochalasin (10μg/mL, 1 day) alleviated CAR molecule transfer.
Nat Genet

Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. [Abstract]

2025 Mar;57(3):680-693. PMID: 40069506

Bezafibrate purchased from MedChemExpress. Usage Cited in: Nat Genet. 2025 Mar;57(3):680-693. [Abstract]

Western blot analysis of CPT1A and PD-L1 levels in cells treated with varying doses of Bezafibrate (BEZ).

Bezafibrate purchased from MedChemExpress. Usage Cited in: Nat Genet. 2025 Mar;57(3):680-693. [Abstract]

Tumor growth of B16F10 cells in immune-normal mice was assessed by treatment with control group, BEZ (Bezafibrate: 15 mg/kg) group, anti-CTLA-4 group, or a combination of both.
J Nanobiotechnology

SIRT5-modified human umbilical cord mesenchymal stem cells loaded with antioxidant polydopamine nanozyme enhance parpi resistance in ovarian cancer via fatty acid metabolism reprogramming. [Abstract]

2025 Jul 4;23(1):485. PMID: 40616128
Adv Sci (Weinh)

Engineered Genetic Circuits Activated by Bezafibrate Improve ESC-Based TAA Cancer Vaccine Efficacy and PD-L1 Nanobody Therapy. [Abstract]

2025 Apr 17:e2500272. PMID: 40245119

Bezafibrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr 17:e2500272. [Abstract]

GFP‐specific fluorescence micrographs of HEK‐293T cells co‐transfected with (PGal4‐RXR,PPPARγ‐p65, P8UAS‐CMV) for 48 h in the presence or absence of 100 µM Bezafibrate.

Bezafibrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr 17:e2500272. [Abstract]

C57BL/6J mice were s.c. injected with HEK 293 cells encapsulated in sodium alginate into the right flank on day 0, followed by s.c immunized on day 7, 14 for three total vaccinations. Bezafibrate (10mg /kg) was administrated i.p. every three days. Anti‐tumor effects of bezafibrate‐triggered target gene expression were assessed.
Cell Rep Med

A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]

2024 May 29:101592. PMID: 38843841
PLoS Biol

Aging-related peroxisomal dysregulation disrupts intestinal stem cell differentiation through alterations of very long-chain fatty acid oxidation. [Abstract]

2025 Dec 19;23(12):e3003552. PMID: 41417787
Ecotoxicol Environ Saf

Excessive selenium affects neural development and locomotor behavior of zebrafish embryos. [Abstract]

2022 Jun 15;238:113611. PMID: 35526456
Biochem Pharmacol

Dual activation of PPARα/γ by bezafibrate triggers PINK1/Parkin-Mediated mitophagy to enhance lenvatinib sensitivity in hepatocellular carcinoma. [Abstract]

2025 Sep 26;242(Pt 3):117367. PMID: 41016578
Life Sci

Low GPR81 in ER+ breast cancer cells drives tamoxifen resistance through inducing PPARα-mediated fatty acid oxidation. [Abstract]

2024 Aug 1:350:122763. PMID: 38823505
J Poult Sci

Fatty acids modulate the expression of pyruvate kinase and arachidonate-lipoxygenase through PPARγ/CYP2C45 pathway: a link to goose fatty liver. [Abstract]

2019 Oct 1;98(10):4346-4358. PMID: 31287882
BMC Cancer

PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis. [Abstract]

2019 Dec 2;19(1):1166. PMID: 31791289
Biochim Biophys Acta Mol Cell Biol Lipids

trans-Cinnamic acid alleviates high-fat diet induced hepatic steatosis by activating AMPK-mTOR pathway. [Abstract]

2026 May;1871(4):159741. PMID: 41932676
Drug Metab Dispos

Metabolic flux analysis of bile acid biosynthesis acidic pathway in HepG2 cells reveals CYP8B1 inhibition of azole antifungals. [Abstract]

2025 Nov;53(11):100168. PMID: 41124962
Biochem Biophys Res Commun

NDRG2 overexpression suppresses hepatoma cells survival during metabolic stress through disturbing the activation of fatty acid oxidation. [Abstract]

2017 Feb 5;483(2):860-866. PMID: 28069379

溶剤 & 溶解度

体外:

DMSO : ≥ 50 mg/mL (138.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7638 mL

13.8190 mL

27.6381 mL

5 mM

0.5528 mL

2.7638 mL

5.5276 mL

10 mM

0.2764 mL

1.3819 mL

2.7638 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[2]

Cell viability is assessed using the CCK-8 kit. Hhuman retinal microvascular endothelial cells (HRMECs) or ARPE-19 cells are seeded at 5000 cells/well in medium containing 10% serum in 96-well plates. After a 24-h incubation, the medium is serum-starved with 1% FBS for 6 h, the CCK-8 reagent is added, and the absorbance of the resultant solution is measured at 450 nm by using a microplate reader at three time points, 24, 48, and 72 h after treatment with Bezafibrate (0, 10, 50, 100, 200, 500, and 1000 μM)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

TallyHo mice are bred in our animal facility. Only male mice are used in the study, and mice receive a standard diet (SD), which is supplemented with 0.5% (w/w) Bezafibrate for the Bezafibrate groups for 8 weeks. Animals are killed by isoflurane overdose, and dissected tissues are prepared as stated below. All data represent samples taken after 8 weeks of Bezafibrate (or SD) treatment unless otherwise stated^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43(4):527-50. [Content Brief]

[2]. Usui-Ouchi A, et al. The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells. Int Immunopharmacol. 2017 Nov;52:70-76. [Content Brief]

[3]. Franko A, et al. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice. Mol Metab. 2017 Jan 6;6(3):256-266. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7638 mL	13.8190 mL	27.6381 mL	69.0951 mL
	5 mM	0.5528 mL	2.7638 mL	5.5276 mL	13.8190 mL
	10 mM	0.2764 mL	1.3819 mL	2.7638 mL	6.9095 mL
	15 mM	0.1843 mL	0.9213 mL	1.8425 mL	4.6063 mL
	20 mM	0.1382 mL	0.6910 mL	1.3819 mL	3.4548 mL
	25 mM	0.1106 mL	0.5528 mL	1.1055 mL	2.7638 mL
	30 mM	0.0921 mL	0.4606 mL	0.9213 mL	2.3032 mL
	40 mM	0.0691 mL	0.3455 mL	0.6910 mL	1.7274 mL
	50 mM	0.0553 mL	0.2764 mL	0.5528 mL	1.3819 mL
	60 mM	0.0461 mL	0.2303 mL	0.4606 mL	1.1516 mL
	80 mM	0.0345 mL	0.1727 mL	0.3455 mL	0.8637 mL
	100 mM	0.0276 mL	0.1382 mL	0.2764 mL	0.6910 mL

Keywords

Bezafibrate

14 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ベザフィブラート

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Anti-Aging Natural Product Library

Cancer Stem Cells Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

RNA Binding Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Bezafibrate

PPAR アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (14)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bezafibrate 関連分類

HY-B0637 関連分類